H.C. Wainwright Thinks Neovasc’s Stock is Going to Recover


In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Neovasc (NVCN), with a price target of $5.00. The company’s shares closed last Wednesday at $1.08, close to its 52-week low of $0.68.

According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 33.2% and a 40.6% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Citius Pharmaceuticals, ENDRA Life Sciences, and Tenax Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Neovasc with a $3.67 average price target.

See today’s analyst top recommended stocks >>

Neovasc’s market cap is currently $72.34M and has a P/E ratio of -0.60. The company has a Price to Book ratio of 35.39.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. Its focuses on Neovast Tiara, and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts